Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion.(b)(4).
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on july 21, 2017.The electronic shipment of the affected product code and lot number from the tennessee distribution center to terumo (b)(4) was tracked.Several shipments were made from the distribution center; however, the total number of units that were described to be ordered and received were not all from this lot.Upon investigating the shipment of the affected product, no issues were noted.The product was not found at the distribution center, and there had been multiple verifications of the shipments accuracy prior to the product leaving the dc.It is possible that there may have been an issue in the shipping after the product left the terumo facility, or there was a miscount of product once it was received; however, neither cause could be confirmed.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|